Terra Alpha Investments LLC Has $3.14 Million Stake in Agilent Technologies, Inc. $A

Terra Alpha Investments LLC boosted its stake in Agilent Technologies, Inc. (NYSE:A) by 10.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,644 shares of the medical research company’s stock after buying an additional 2,415 shares during the quarter. Agilent Technologies makes up about 3.3% of Terra Alpha Investments LLC’s investment portfolio, making the stock its 13th largest position. Terra Alpha Investments LLC’s holdings in Agilent Technologies were worth $3,144,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also bought and sold shares of A. Brighton Jones LLC boosted its stake in Agilent Technologies by 6.1% in the 4th quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock valued at $626,000 after buying an additional 270 shares in the last quarter. GAMMA Investing LLC boosted its stake in Agilent Technologies by 34.6% in the 1st quarter. GAMMA Investing LLC now owns 5,362 shares of the medical research company’s stock valued at $627,000 after buying an additional 1,379 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Agilent Technologies by 86.3% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 51,363 shares of the medical research company’s stock valued at $6,009,000 after buying an additional 23,800 shares in the last quarter. Blue Trust Inc. boosted its stake in Agilent Technologies by 8.0% in the 1st quarter. Blue Trust Inc. now owns 1,763 shares of the medical research company’s stock valued at $206,000 after buying an additional 131 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its stake in Agilent Technologies by 2.4% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 47,918 shares of the medical research company’s stock valued at $5,605,000 after buying an additional 1,110 shares in the last quarter.

Agilent Technologies Price Performance

Agilent Technologies stock opened at $145.79 on Wednesday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. The firm has a market cap of $41.33 billion, a P/E ratio of 34.22, a P/E/G ratio of 4.67 and a beta of 1.26. The business’s fifty day moving average is $128.72 and its two-hundred day moving average is $118.37. Agilent Technologies, Inc. has a 52 week low of $96.43 and a 52 week high of $153.84.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.67 billion. During the same quarter in the prior year, the firm posted $1.32 earnings per share. The firm’s revenue for the quarter was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities research analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 22nd. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Tuesday, September 30th. Agilent Technologies’s dividend payout ratio is 23.24%.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Wall Street Zen raised Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. Rothschild Redb raised Agilent Technologies to a “strong-buy” rating in a research note on Wednesday, October 8th. TD Cowen boosted their price target on Agilent Technologies from $150.00 to $162.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. JPMorgan Chase & Co. boosted their price objective on Agilent Technologies from $155.00 to $165.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Finally, Wells Fargo & Company boosted their price objective on Agilent Technologies from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Monday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $149.62.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.